Intellia Therapeutics, Inc. $NTLA Holdings Raised by Vanguard Group Inc.

Vanguard Group Inc. grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 17.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,010,001 shares of the company’s stock after acquiring an additional 1,965,181 shares during the quarter. Vanguard Group Inc. owned approximately 0.11% of Intellia Therapeutics worth $116,960,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Contrarius Group Holdings Ltd increased its holdings in shares of Intellia Therapeutics by 279.4% in the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after acquiring an additional 4,337,428 shares during the last quarter. Baker BROS. Advisors LP increased its holdings in shares of Intellia Therapeutics by 2.7% in the 3rd quarter. Baker BROS. Advisors LP now owns 2,746,674 shares of the company’s stock valued at $47,435,000 after acquiring an additional 71,000 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of Intellia Therapeutics by 7.6% in the 3rd quarter. Two Sigma Investments LP now owns 2,449,607 shares of the company’s stock valued at $42,305,000 after acquiring an additional 173,033 shares during the last quarter. Voloridge Investment Management LLC boosted its position in Intellia Therapeutics by 3.7% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,610,205 shares of the company’s stock valued at $27,808,000 after purchasing an additional 56,971 shares during the period. Finally, Jupiter Asset Management Ltd. acquired a new position in Intellia Therapeutics during the 3rd quarter valued at approximately $23,519,000. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $13.99 on Wednesday. Intellia Therapeutics, Inc. has a 1 year low of $6.83 and a 1 year high of $28.25. The stock has a fifty day moving average of $13.67 and a two-hundred day moving average of $12.15. The firm has a market capitalization of $1.69 billion, a PE ratio of -3.95 and a beta of 1.93.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 55.63% and a negative net margin of 597.04%.The company had revenue of $15.05 million during the quarter, compared to analyst estimates of $13.81 million. Equities research analysts predict that Intellia Therapeutics, Inc. will post -3.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on NTLA shares. Truist Financial upgraded Intellia Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Robert W. Baird boosted their price objective on Intellia Therapeutics from $7.00 to $13.00 and gave the company a “neutral” rating in a research report on Monday, April 27th. JonesTrading upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research report on Wednesday, March 4th. HC Wainwright boosted their price objective on Intellia Therapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Finally, Wedbush restated a “neutral” rating and set a $12.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Hold” and an average price target of $20.36.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.